Forum Agenda

July 23,09:00-12:00

Merits & Tree Law Offices Session:From IP to BD: China Innovative Drug Transaction Competency

Stay tuned

Meeting Planner
Tang Huadong:Partner, Merits & Tree Law Offices

Zhu Pengcheng:Founder & CEO, ATLATL Innovation Center
Guo Xiaoxing:Partner, Merits & Tree Law Offices
Huang Xiaolin(Moderator):Partner, Merits & Tree Law Offices


09:00-09:05 Opening Remarks: Why the Shift from IP to BD Deal-Making Capability Matters
Tang Huadong:Partner, Merits & Tree Law Offices


09:05-09:20 Keynote I: From IP to BD — The Six Core Drivers of Deal-Making Power in China's Innovative Drug Transactions
Tang Huadong:Partner, Merits & Tree Law Offices


09:20-09:40 Keynote II: Accelerating the IP-to-BD Journey with a "Super-Server" — ATLATL's Engineering Practice
Zhu Pengcheng:Founder & CEO, ATLATL Innovation Center


09:40-10:00 Keynote III: Compliance Red Lines in Innovative Drug BD Transactions
Guo Xiaoxing:Partner, Merits & Tree Law Offices


10:00-10:20 Keynote IV: IP Challenges and Opportunities for Innovators in a Highly Competitive Landscape
Lao Fang:IP Director, METiS TechBio


10:20-10:40 Keynote V: Business Development and Global Partnership Pathways for Chinese Biotech Enterprises
Eric Li: Managing Director & Head of China, Locust Walk

 

10:40-10:45 Transition: BD Deal-Making Capability Assessment Portal
Tang Huadong:Partner, Merits & Tree Law Offices


10:45-11:50 Panel Discussion: From BP to Term Sheet — Key Bottlenecks and Breakthrough Paths in Chinese Innovative Drug BD Transactions
Moderator:
Huang Xiaolin : Partner, Merits & Tree Law Offices
Panelists:
Du Shanshan:China Regulatory Affairs Director, Servier
Guo Lianyu:External Innovation Director, R&D, Servier
Guo Songxi:Head of IP, Astellas China

David Miao:Chairman & CEO, Imbioray Biopharm Chief Scientific Advisor, Hangzhou Adcoris BioPharma

 

11:50-12:00 Summarize

Tang Huadong:Partner, Merits & Tree Law Offices